ClinicalTrials.gg
RecruitingNCT07014293Updated Sep 28, 2026

Increasing Resiliency Among Early Post-Treatment Lymphoma Survivors

An interventional study of Enhanced Usual Care and SMART3RP-Lymphoma in Lymphoma, sponsored by Massachusetts General Hospital. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-28.

Sponsored by Massachusetts General Hospital · Not applicable, Interventional, and Supportive care

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Sep 28, 2026Start date movedEligibility revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
254
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies in Lymphoma by Massachusetts General Hospital — 4 open to participants now, 5 under way, none of them phase 3. Lymphoma · Massachusetts General Hospital.

Planned enrollment
2nd of 23
254 · median 18
Started
2026
with 2 others
No phase
9 of 24
3 open now
Registered
22nd of 24
by date

Among the 24 studies in Lymphoma by Massachusetts General Hospital, this one is the 2nd largest by planned enrollment of the 23 interventional ones that give a count, is one of 3 that started in 2026, is one of 9 with no phase, and was the 22nd registered.

Lymphoma

3,018 studies on the registry are indexed under Lymphoma; 433 are open to participants now.

Browse Lymphoma studies →

Open to participants now

4 of the 24 studies in Lymphoma by Massachusetts General Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 346 Lymphoma studies recruiting now, 227 (66%) set no upper age limit and 78 (23%) stop at 75 or younger; 77 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Lymphoma by Massachusetts General Hospital, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if a mind body resilience group program can help increase lymphoma survivors' ability to cope with and manage the challenges that come with the transition into early post treatment survivorship.

Read the detailed description

This is a randomized controlled trial assessing the effects of the Stress Management and Resiliency Training: Relaxation Response Resiliency-Lymphoma (SMART3RP-Lymphoma) compared to Enhanced Usual Care on 254 early post treatment lymphoma survivors. The SMART-3RP is a comprehensive, evidence-based mind body group program designed to help individuals adapt to chronic stress (i.e., increase their resilience). It understands the adjustment to chronic stress as a dynamic process, blending CBT, positive psychology and mind body tools to target key coping processes.

This trial seeks to answer the following questions:

  • Will survivors randomized to SMART3RP-Lymphoma demonstrate greater improvements in coping skills when compared to survivors randomized to enhanced usual care?
  • Do factors, such as age, sex, race/ethnicity, rural/urban living, socioeconomic status, impact how survivors respond to the treatment?

Of note: This record describes our primary aim to compare the effects of SMART3RP-Lymphoma to enhanced usual care on lymphoma survivors' coping with the adjustment to posttreatment survivorship. While this trial will explore potential sociodemographic moderators of the main intervention effects on our primary aim (Aim 1), given the exploratory nature of these analyses (i.e., hypothesis-generating), we will not report the results of our moderation analyses in this record but rather focus on the main effects of the study intervention.

03

Conditions studied

  • Lymphoma

Browse trials for

Keywords

  • coping
  • psychosocial intervention
  • survivorship
  • resilience
04

Who can participate

The criteria were revised on the registry on Sep 28, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • English speaking adult (18 years or older at enrollment)
  • Is at least 6 months post-diagnosis and a) is currently undergoing lymphoma treatment (includes surgery, chemotherapy/immunotherapy/radiation therapy, or other) with evidence of treatment response or disease control; or b) has completed lymphoma treatment (e.g., chemotherapy/immunotherapy/radiation therapy, surgery or other) within the past 2 years and has disease control at treatment completion; patients may still be on maintenance treatment to prolong disease control.

Exclusion criteria

Exclusion Criteria:

  • Has not initiated treatment for lymphoma.
  • Has worsening, progressive, or uncontrolled disease that is not responding to treatment.
  • Active Psychiatric, medical or cognitive comorbidity as determined by site PI or treating clinician
  • Unwilling or unable to participate using telehealth platform
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
254 participants (estimated)

Study arms

  • Other
    Enhanced Usual Care

    Participants randomized to EUC will be referred to their site social work team. This most closely resembles the real-world care available to survivors on an outpatient basis. It is an enhanced version of usual care because proactive identification and referral of posttreatment survivors is not routinely done.

    Other: Enhanced Usual Care

  • Experimental
    SMART3RP-Lymphoma

    Participants will participate in 8 weekly group sessions, delivered virtually. The intervention components include: 1. Eliciting the relaxation response (RR) involves sustained mental focus with an attitude of open receptive awareness. 2. CBT to improve stress management involves increasing awareness and identification of the components of one's stress response (negative thoughts, emotions, physical reactions, behaviors, and relational) and learning skills at each session to alter these components (e.g., cognitive restructuring). 3. Positive psychology strategies to achieve growth enhancement focus on utilizing techniques and skills to promote positive growth. Skills focus on increasing social support, positive affect, and compassion.

    Other: SMART3RP-Lymphoma

Interventions

  • OtherEnhanced Usual Care

    Participants will receive a singleevaluation with a site social worker along with a list of mental health, social or community resources . This most closely resembles the real-world care available to survivors on an outpatient basis, however, we call this enhanced usual care since proactive identification and referral of posttreatment survivors is not routinely done.

  • OtherSMART3RP-Lymphoma

    The intervention components include: 1. Eliciting the relaxation response (RR) involves sustained mental focus with an attitude of open receptive awareness. 2. CBT to improve stress management involves increasing awareness and identification of the components of one's stress response (negative thoughts, emotions, physical reactions, behaviors, and relational) and learning skills at each session to alter these components (e.g., cognitive restructuring). 3. Positive psychology strategies to achieve growth enhancement focus on utilizing techniques and skills to promote positive growth. Skills focus on increasing social support, positive affect, and compassion.

06

What researchers measure

Primary outcomes

  1. Change from Baseline in Coping Scores on the Measure of Current Status Scale (MOCS-A)

    The Measure of Current Status Scale (MOCS-A) measures coping processes on 4 domains: ability to relax, recognize stress, elicit support, and restructure thoughts. It is a 13-item scale where each item is measured on a 0-4 scale.

    Time frame: Baseline to 3 month follow up

Secondary outcomes

  1. Change in Anxiety Symptoms Based on the Generalized Anxiety Disorder Scale-7 (GAD-7)

    The Generalized Anxiety Disorder Scale-7 (GAD-7) is a 7-item self-report measure assessing symptoms of anxiety. Items are rated on a 0 to 3 scale and summed to produce a total score ranging from 0 to 21. Higher scores indicate greater anxiety symptom severity.

    Time frame: Enrollment to 3 month follow up

  2. Change in Depressive Symptoms Based on the Patient Health Questionnaire-8 (PHQ-8)

    The Patient Health Questionnaire-8 (PHQ-8) is an 8-item self-report measure assessing symptoms of depression. Items are rated on a 0 to 3 scale and summed to produce a total score ranging from 0 to 24. Higher scores indicate greater depressive symptom severity.

    Time frame: Enrollment to 3 month follow up

  3. Change in Physical Health (PROMIS Physical Function-8b)

    The PROMIS Physical Function-8b is an 8-item measure that assesses the ability to perform daily living activities. Each item is scored on a scale of 1 (Unable to do) to 5 (Without any difficulty).

    Time frame: Enrollment to 3 month follow up

  4. Change in Quality of Life Based on the Functional Assessment of Cancer Therapy-General (FACT-G)

    The Functional Assessment of Cancer Therapy-General (FACT-G) is a 27-item self-report measure assessing overall quality of life across four domains: physical well-being, functional well-being, emotional well-being, and social/family well-being. Items are rated on a 0 (not at all) to 4 (very much) scale and summed to produce a total score ranging from 0 to 108. Higher scores indicate better quality of life.

    Time frame: Enrollment to 3 month follow up

  5. Change in Quality of Life Based on the PROMIS Global-10

    The PROMIS Global-10 is a 10-item measure assessing overall quality of life. Responses are converted to standardized T-scores (mean = 50, standard deviation = 10), with possible scores ranging approximately from 0 to 100. Higher T-scores indicate better overall quality of life.

    Time frame: Enrollment to 3 month follow up

  6. Change in Resilience scores (Current Experiences Scale (CES-23))

    The CES-23 is a 23-item measure that assesses resilience on 6 dimensions: appreciation for life, adaptive perspectives, personal strength, spiritual connectedness, relating to others, and health behaviors. Each item is scored on a 0 (not at all) to 5 (to a very great degree) scale.

    Time frame: Enrollment to 3 month follow up

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Jul 2030, 45 months after the start.

Of 161 non-industry interventional studies with no phase under Lymphoma, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 87. This study's planned 45 months is close to that.

Counting every sponsor, half of 170 studies reached it within 43 months; a quarter within 23 and three quarters within 87.

Start moved once since we started tracking on Sep 25, 2026: Aug 2026 → Sep 2026, on Sep 28, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 23, 2025
First posted
Jun 10, 2025
StartActual
Sep 3, 2026was Aug 2026
Primary completionEst.
Jul 1, 2030
CompletionEst.
Jul 1, 2030
Last update
Sep 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Aug 31, 2026→Sep 3, 2026 (actual)
Sep 28, 2026
Eligibility
1 inclusion criterion added, 1 removed; 1 exclusion criterion edited, 2 added
What changed in the criteria
Inclusion criteria
  • RemovedAt least 6-months post-lymphoma diagnosis and within 2 years of completing active, curative treatment for lymphoma (includes surgery, chemotherapy/immunotherapy/radiation therapy, or other)
  • AddedIs at least 6 months post-diagnosis and a) is currently undergoing lymphoma treatment (includes surgery, chemotherapy/immunotherapy/radiation therapy, or other) with evidence of treatment response or disease control; or b) has completed lymphoma treatment (e.g., chemotherapy/immunotherapy/radiation therapy, surgery or other) within the past 2 years and has disease control at treatment completion; patients may still be on maintenance treatment to prolong disease control.
Exclusion criteria
  • AddedHas not initiated treatment for lymphoma.
  • AddedHas worsening, progressive, or uncontrolled disease that is not responding to treatment.
  • EditedActive Psychiatric, medical or cognitive comorbidity as determined by site PI or treating clinician
Sep 28, 2026
Show all 1 update
  1. Sep 28, 2026
    Start date Aug 31, 2026→Sep 3, 2026 (now actual)
    Eligibility 1 inclusion criterion added, 1 removed; 1 exclusion criterion edited, 2 added
    What changed in the criteria
    Inclusion criteria
    • RemovedAt least 6-months post-lymphoma diagnosis and within 2 years of completing active, curative treatment for lymphoma (includes surgery, chemotherapy/immunotherapy/radiation therapy, or other)
    • AddedIs at least 6 months post-diagnosis and a) is currently undergoing lymphoma treatment (includes surgery, chemotherapy/immunotherapy/radiation therapy, or other) with evidence of treatment response or disease control; or b) has completed lymphoma treatment (e.g., chemotherapy/immunotherapy/radiation therapy, surgery or other) within the past 2 years and has disease control at treatment completion; patients may still be on maintenance treatment to prolong disease control.
    Exclusion criteria
    • AddedHas not initiated treatment for lymphoma.
    • AddedHas worsening, progressive, or uncontrolled disease that is not responding to treatment.
    • EditedActive Psychiatric, medical or cognitive comorbidity as determined by site PI or treating clinician
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07014293
Responsible party
Giselle K. Perez Lougee (Clinical Psychologist, Massachusetts General Hospital) — Principal investigator
First posted
Jun 10, 2025
Start date
Sep 3, 2026
Primary completion
Jul 1, 2030 (estimated)
Completion
Jul 1, 2030 (estimated)
Last update
Sep 28, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion